CRNX vs INCY
Crinetics Pharmaceuticals, Inc. vs Incyte — AI-powered side-by-side comparison
CRNX
Crinetics Pharmaceuticals, Inc.
65
Buy
VS
| Metric | CRNX | INCY |
|---|
| AI Score |
65
|
72
|
| Price |
$84.35
|
$121.08
|
| P/E Ratio |
-16.70×
|
14.89×
|
| ROE |
-46.9%
|
24.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.2%
|
92.6%
|
| Debt / Equity |
0.00×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
89.2
|
56.2
|
| Beta |
0.1302
|
0.769
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for CRNX versus INCY.
INCY leads by 7 points.
INCY scores 72/100 (Buy) versus CRNX at 65/100 (Buy).
CRNX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 2928.4% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 4.5x prices in significant intangible value — Value
- ROE of only -44.2% -- cheap may mean cheap for a reason — Value
- RSI at 89 is in overbought territory — Technical
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical